Cheapest GLP-1 Provider 2026

1. 2026 price tiers (full overview)

GLP-1 access in 2026 splits across five effective price tiers, each with different trade-offs on FDA-status, support quality, and supply continuity:

2. Tier 1: $0-25/month with insurance + savings

The cheapest sustainable path is commercial insurance coverage combined with a manufacturer savings card.

• NovoCare savings card (Wegovy, Ozempic, Rybelsus): $0-25/month copay for commercially-insured patients, with a per-card cap (Rybelsus pays at most $100/month). Saxenda and Victoza no longer have a card — Novo closed the Saxenda offer in 2023 and Victoza left the US market in April 2024.
• LillyCares savings (Zepbound, Mounjaro, Trulicity): Similar $0-25/month copay assistance for commercial insurance.

Excluded: Medicare, Medicaid, federally-funded plans (TRICARE, VA), uninsured patients. These exclusions are due to federal anti-kickback rules that prevent manufacturer subsidies of government-funded prescriptions.

For Medicare patients: Wegovy is now covered under its 2024 cardiovascular indication for eligible Part D patients with established CVD. See our Insurance Coverage 2026 guide for full Medicare + Medicaid landscape.

3. Tier 2: $149/month, and it is now FDA-approved

This tier used to belong to compounded semaglutide. It no longer does. Two FDA-approved daily tablets are sold direct by their manufacturers at the same price compounded programmes advertise:

• Oral Wegovy (semaglutide tablets): $149/month for the 1.5 mg and 4 mg strengths, $299/month for 9 mg and 25 mg. The 4 mg price is introductory and rises to $199/month after 31 August 2026.
• Foundayo (orforglipron): $149/month at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 mg and above.

Compounded semaglutide through telehealth still advertises from about $99-199/month, so the saving over an approved tablet is now small or nil — and it buys a product the FDA has not reviewed for safety, effectiveness or manufacturing quality. We are not listing per-provider compounded floors here any more: several of the companies that held the lowest advertised prices received FDA warning letters on 20 February 2026, and quoting a headline price next to a company name reads as a recommendation whether or not it is meant as one.

Important trade-offs:

• NOT FDA-approved as finished product — see our compounded buyer's guide for safety + verification
• The legal basis narrowed sharply once the FDA declared the semaglutide and tirzepatide shortages resolved — mass compounding of copies was permitted because of the shortage, and that justification is gone
• 30+ compounding companies received FDA enforcement actions in 2026
• Hims exited compounded GLP-1s in early 2026 — signal that the category is shrinking
• Supply continuity is not guaranteed — a programme priced below the approved tablets depends on a compounder keeping access, and on 20 February 2026 the FDA sent roughly 30 warning letters to telehealth companies in this category in a single day

4. Tier 3: $299–$699/month LillyDirect Zepbound

Eli Lilly's LillyDirect program sells Zepbound single-dose vials direct-to-consumer at fixed cash prices, regardless of insurance status:

• Zepbound 2.5 mg: $299/mo (2.5 mg)[zepbound]
• Zepbound 5 mg: $399/mo (5 mg)[zepbound]
• Zepbound 7.5 mg: $499/mo (7.5 mg)[zepbound]
• Zepbound 10, 12.5 and 15 mg: $699/mo (10, 12.5, 15 mg)[zepbound]
• On Lilly's 45-day auto-refill purchase offer, 7.5 mg and up hold at $449/mo (7.5 mg and up)[zepbound]

This is the cheapest FDA-approved tirzepatide path in 2026. Key features:

• FDA-approved finished product (Zepbound, full FDA oversight)
• Direct from manufacturer (no pharmacy markup)
• Cash-pay only — does not bill insurance
• Available nationwide
• Self-injection from vial (vs autoinjector pens) — slightly more dexterity required

For semaglutide-equivalent FDA-approved option, Novo Nordisk launched a similar Wegovy direct program in 2025 but pricing has been higher, but NovoCare cut Wegovy self-pay to ~$349/month in 2026 — now comparable to LillyDirect. Compare both via our Wegovy and Zepbound drug pages.

5. Tier 4: $349/month NovoCare Wegovy (uninsured)

NovoCare offers a savings program for uninsured Wegovy patients that brings monthly cost to approximately $349 (with a ~$199/month introductory offer) — about a quarter of full retail. Eligibility:

• US adults aged 18+
• Uninsured (no commercial coverage, not on Medicare/Medicaid)
• Valid prescription for Wegovy
• Application through Novo Nordisk Patient Assistance enrollment

This is the cheapest FDA-approved semaglutide for the uninsured. The annual cost (~$7,800) is still substantial — if $349/month exceeds your budget, the compounded tier 2 or LillyDirect Zepbound tier 3 (different molecule but same weight-loss outcome category) may be more accessible.

6. Tier 5: Full retail $998-1,349/month

Without insurance or savings programs, list prices are:

• Wegovy: $1,349/month
• Saxenda: $1,349/month
• Mounjaro: $1,069/month
• Zepbound: $1,086/month
• Ozempic: $998/month
• Rybelsus: $998/month
• Trulicity: $987/month

Few patients pay full retail in practice — most have either insurance coverage, savings card eligibility, or use a manufacturer-direct or compounded program. If you're paying retail, you almost certainly have a cheaper option available; start with our Insurance Coverage 2026 guide to identify which tier you qualify for.

7. The 2026 compounding crackdown

Key events shaping the 2026 compounded GLP-1 landscape:

• February 2025: FDA resolves semaglutide shortage. Legal basis for mass-compounding under shortage exemption ends.
• March 2025: Compounding industry groups file litigation challenging FDA resolution; partial injunctions issued in some districts.
• Late 2025: FDA issues warning letters to multiple compounding pharmacies; first round of enforcement actions.
• Early 2026: Hims announces exit from compounded GLP-1 category. Other major telehealth platforms scale back.
• Mid-2026: FDA enforcement against 30+ companies. Compounded GLP-1 market continues shrinking but smaller compounders remain.

Expected through 2026-2027: continued enforcement, possible settlement or legal clarity for traditional 503A compounding, continued telehealth platform consolidation toward FDA-approved options.

8. Interactive cost projection

Project your 12, 24, and 36-month total spend by drug + coverage scenario:

9. Decision tree by your situation

• If you have commercial insurance: First check if your plan covers Wegovy or Zepbound. If yes, add the manufacturer savings card → $0-25/month. This is the cheapest sustainable path.
• If you have Medicare: Check if you qualify for Wegovy CVD coverage (established cardiovascular disease + BMI ≥27). Diabetes-indicated GLP-1s (Ozempic, Mounjaro) typically covered.
• If you have Medicaid: Check state-specific coverage. About 13 states cover GLP-1s for chronic weight management.
• If you're uninsured + want FDA-approved: LillyDirect Zepbound ($299–$699/month) is the cheapest. NovoCare Wegovy (~$349/month) if you specifically need semaglutide.
• If cost is the primary barrier: Compounded semaglutide ($129-199/month) via verified state-licensed pharmacy. Read our buyer's guide first.
• If you're not sure where you fit: Take our 3-question quiz for a personalized recommendation.

10. Frequently asked questions

What is the cheapest GLP-1 medication in 2026?

With commercial insurance and a manufacturer savings card, $0-25/month. Without insurance, the cheapest FDA-approved routes are now the daily tablets: oral Wegovy at $149/month for the 1.5 mg and 4 mg strengths, and Foundayo (orforglipron) at $149/month for 0.8 mg, both direct from the manufacturer. Zepbound vials start at $299/month. That matters because it closes the old gap: compounded semaglutide programmes advertise from roughly $99-199/month, so an FDA-approved tablet now costs about what a non-FDA-approved compounded vial does.

Is $129/month for semaglutide too good to be true?

It's real but comes with trade-offs. Compounded semaglutide at this price is NOT FDA-approved as a finished product. The FDA resolved the semaglutide shortage in February 2025, narrowing the legal basis for mass compounding. In 2026, the FDA has taken enforcement actions against 30+ compounding companies. Lower prices reflect lower regulatory oversight, not lower-quality molecule — but quality and legal availability depend on the specific pharmacy.

What's the cheapest FDA-approved GLP-1 in 2026?

LillyDirect Zepbound at $299/month for the 2.5 mg starting dose, rising to $699/month at the 10, 12.5 and 15 mg maintenance doses, is the cheapest FDA-approved route. Note Lilly prices the KwikPen and the vial the same — the vial is not the cheaper format — and a separate purchase offer holds 7.5 mg and up at $449/month while you stay on its 45-day refill schedule. This is direct-from-manufacturer cash-pay (not through insurance). For semaglutide specifically, NovoCare self-pay can lower Wegovy to ~$349/month for maintenance doses (with a ~$199/month introductory offer) for uninsured patients. With commercial insurance + savings cards, both Wegovy and Zepbound can drop to $0-25/month copay.

Why did Hims exit compounded GLP-1s?

In early 2026, Hims announced it would stop offering compounded GLP-1 medications. The decision followed FDA enforcement actions against compounding manufacturers post-shortage-resolution. Hims continues to offer FDA-approved Wegovy through partner pharmacies. The exit signals broader market shift toward FDA-approved options as the compounding legal landscape narrows.

Can I get GLP-1 free or near-free with insurance?

Yes, if you qualify. Commercial insurance with a manufacturer savings card (NovoCare for Wegovy/Ozempic/Rybelsus, Lilly’s own card for Zepbound/Mounjaro/Trulicity) can reduce copay to $0-25/month. Eligibility excludes Medicare, Medicaid, and uninsured patients. Each card caps what it will pay rather than sharing one common limit — Trulicity stops at $1,950 a year, Rybelsus at $100 a month — so check the cap on the card you are handed. For Medicare beneficiaries, Wegovy is now covered under its 2024 cardiovascular indication for eligible patients.

Is the cheapest option always the best?

No. The "cheapest" question hides three trade-offs: (1) regulatory oversight — compounded products are not FDA-reviewed as finished products; (2) supply continuity — compounded programs may face legal restrictions; (3) provider support quality — bundled telehealth programs offer dose titration support and prescriber access that DIY routes don't. Pick based on your priorities: cost, oversight, support level, and risk tolerance.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

Pricing reflects publicly-stated 2026 cost structures and is subject to change. Compounded products are NOT FDA-approved as finished products. GLP1Zoom is affiliate-disclosed and earns commission from some partner providers; this guide includes providers regardless of partnership status. Always confirm current pricing directly with providers. Full disclaimer.